Chilongola Jaffu, Ndaro Arnold, Tarimo Hipolite, Shedrack Tamara, Barthazary Sakurani, Kaaya Robert, Masokoto Alutu, Kajeguka Debora, Kavishe Reginald A, Lusingu John
Kilimanjaro Christian Medical University College and Kilimanjaro Clinical Research Institute, Moshi, Tanzania.
Sokoine University of Agriculture, Morogoro, Tanzania.
Malar Res Treat. 2015;2015:279028. doi: 10.1155/2015/279028. Epub 2015 Jan 5.
We aimed to determine the current prevalence of four P. falciparum candidate artemisinin resistance biomarkers L263E, E431K, A623E, and S769N in the pfatpase6 gene in a high transmission area in Tanzania in a retrospective cross sectional study using 154 archived samples collected from three previous malaria studies in 2010, 2011 and 2013. Mutations in pfatpase6 gene were detected in parasite DNA isolated from Dried Blood Spots by using PCR-RFLP. We observed overall allelic frequencies for L263E, E431K, A623E, and S769N to be 5.8% (9/154), 16.2% (25/154), 0.0% (0/154), and 3.9% (6/154). The L263E mutation was not detected in 2010 but occurred at 3.9% and 2.6% in 2011 and 2013 respectively. The L263E mutation showed a significant change of frequency between 2010 and 2011, but not between 2011 and 2013 (P < 0.05). Frequency of E431K was highest of all without any clear trend whereas S769N increased from 2.2% in 2010 to 3.6% in 2011 and 5.1% in 2013. A623E mutation was not detected. The worrisome detection and the increase in the frequency of S769N and other mutations calls for urgent assessment of temporal changes of known artemisinin biomarkers in association with in vivo ACT efficacy.
我们旨在通过一项回顾性横断面研究,利用2010年、2011年和2013年之前三项疟疾研究收集的154份存档样本,确定坦桑尼亚一个高传播地区恶性疟原虫青蒿素抗性候选生物标志物L263E、E431K、A623E和S769N在pfatpase6基因中的当前流行情况。通过PCR-RFLP检测从干血斑中分离的寄生虫DNA中pfatpase6基因的突变。我们观察到L263E、E431K、A623E和S769N的总体等位基因频率分别为5.8%(9/154)、16.2%(25/154)、0.0%(0/154)和3.9%(6/154)。L263E突变在2010年未检测到,但在2011年和2013年分别为3.9%和2.6%。L263E突变在2010年至2011年之间频率有显著变化,但在2011年至2013年之间没有(P<0.05)。E431K的频率在所有突变中最高,没有明显趋势,而S769N从2010年的2.2%增加到2011年的3.6%和2013年的5.1%。未检测到A623E突变。S769N和其他突变令人担忧的检测结果及频率增加,需要对已知青蒿素生物标志物的时间变化与体内青蒿素联合疗法疗效进行紧急评估。